Aclaris Therapeutics

Liquidity is the main strength: 190.8 million dollars of cash, cash equivalents and marketable securities as of March 31, 2026, and management’s stated runway through year‑end 2028. Operating cash outflow in Q1 2026 was 18.1 million dollars, suggesting more than 10 quarters of runway at recent pace. There is no material debt disclosed.

The company also monetized a portion of OLUMIANT royalties to OMERS for 26.5 million dollars, recognizes related non‑cash royalty income, and raised 57.9 million dollars via ATM in March 2026. Share count is 139.7 million as of April 30, 2026, and outstanding low‑strike warrants from the Biosion deal contribute to dilution.

Score reflects strong near‑term solvency offset by dilution risk and the inevitable need for additional capital absent approvals or partnerships by 2029.